SG Americas Securities LLC Makes New $637,000 Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

SG Americas Securities LLC bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 31,051 shares of the company's stock, valued at approximately $637,000.

Other hedge funds have also recently modified their holdings of the company. Kynam Capital Management LP increased its stake in shares of Syndax Pharmaceuticals by 41.5% during the 4th quarter. Kynam Capital Management LP now owns 5,660,000 shares of the company's stock worth $122,313,000 after purchasing an additional 1,660,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Syndax Pharmaceuticals by 13.6% during the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company's stock worth $117,262,000 after purchasing an additional 591,631 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in shares of Syndax Pharmaceuticals by 65.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,222,222 shares of the company's stock worth $91,242,000 after purchasing an additional 1,666,667 shares during the last quarter. Avidity Partners Management LP increased its stake in shares of Syndax Pharmaceuticals by 40.0% during the 4th quarter. Avidity Partners Management LP now owns 3,950,000 shares of the company's stock worth $85,360,000 after purchasing an additional 1,129,000 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Syndax Pharmaceuticals by 35.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,834,499 shares of the company's stock valued at $61,254,000 after buying an additional 740,298 shares in the last quarter.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan acquired 1,250 shares of the firm's stock in a transaction on Friday, June 14th. The shares were purchased at an average price of $20.03 per share, for a total transaction of $25,037.50. Following the completion of the transaction, the chief financial officer now owns 52,623 shares of the company's stock, valued at $1,054,038.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on SNDX. HC Wainwright lifted their price objective on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. Barclays lifted their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research note on Thursday, August 15th. Jefferies Financial Group began coverage on shares of Syndax Pharmaceuticals in a research note on Friday, June 28th. They issued a "buy" rating and a $37.00 price objective for the company. Bank of America lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. Finally, Stifel Nicolaus boosted their price target on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a "buy" rating in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $35.33.

Syndax Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ SNDX traded down $0.06 during mid-day trading on Tuesday, reaching $20.44. 604,975 shares of the company were exchanged, compared to its average volume of 1,100,924. Syndax Pharmaceuticals, Inc. has a 52 week low of $11.22 and a 52 week high of $25.34. The stock has a market capitalization of $1.74 billion, a PE ratio of -6.35 and a beta of 0.94. The company's 50 day moving average price is $21.26 and its 200 day moving average price is $21.68.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.11. The business had revenue of $3.50 million during the quarter. During the same period in the previous year, the company earned ($0.64) earnings per share. The firm's revenue was up 3499999990.0% compared to the same quarter last year. On average, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.64 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).